Nanoscope Therapeutics announced that new post-hoc clinical analyses of its lead optogenetic therapy, MCO-010, will be presented at the 2026 Macula Society Annual Meeting being held February 25–28 in San Diego.

The data will be presented by Christine N. Kay, MD, Director of Clinical Research and Retinal Genetics at Vitreoretinal Associates in Gainesville, Florida. Dr. Kay will share findings from long-term follow-up of the company’s 3-year randomized phase 2b/3 clinical trials, RESTORE and REMAIN. The multivariant analysis examines patient and disease characteristics associated with the strongest visual improvement outcomes following a one-time treatment with MCO-010 in patients with retinitis pigmentosa (RP) and severe vision loss.

The presentation, titled “Vision Improvement Outcomes in Retinitis Pigmentosa: Multivariant Analysis from 3-Year RESTORE and REMAIN Data of MCO-010 Optogenetic Gene Therapy,” will take place during the session Inherited Dystrophy I: Clinical Trials and Beyond on Friday, February 27, from 7:30 a.m. to 7:35 a.m.

According to Dr. Kay, the new analyses represent a critical step in interpreting the broader phase 3 dataset.

“These analyses are an important next step in helping to understand the phase 3 clinical trial data of MCO-010 in retinitis pigmentosa,” Dr. Kay said. “By examining the characteristics of patients who had the best outcomes across three years of follow-up in RESTORE and REMAIN, we can begin to understand how the therapy can be used in patients in the real world, if approved.”

MCO-010 is part of Nanoscope’s broader MCO platform, a one-time, in-office intravitreal therapy designed to restore vision in patients with photoreceptor degeneration, including RP, Stargardt disease, and geographic atrophy. The optogenetic approach works by activating dense bipolar retinal cells to become light-sensitive, leveraging the remaining visual circuitry after photoreceptor death.